Bexacat Flavored Tablet
Bexacat is an FDA-approved preparation containing Bexacat, for veterinary use. Available by prescription.
Veterinarians most commonly consider Bexacat™ for feline patients presented with newly diagnosed diabetes mellitus that have not yet received insulin therapy. It is frequently a point of discussion for endocrine health protocols where an oral daily medication is preferred over injectable options. By modulating the way the kidneys process glucose, your veterinarian can manage the circulating blood sugar levels without the physiological requirement for exogenous insulin administration.
At a pharmacological level, bexagliflozin acts by inhibiting the SGLT2 protein located in the proximal renal tubules of the kidney. This protein is responsible for the majority of glucose reabsorption from the glomerular filtrate back into the bloodstream. By blocking this transporter, the medication help address the reabsorption process, resulting in the excretion of excess glucose through the urine (glucosuria). This insulin-independent mechanism manages blood glucose concentrations by physically removing sugar from the systemic circulation. Your veterinarian will determine the clinical appropriateness of this medication based on specific diagnostic testing results, including a complete blood count, chemistry profile and urinalysis to confirm the patient’s metabolic status.
The actions described here reflect the product's FDA-approved labeling; your veterinarian determines the appropriate use for your animal.
Prescription only. Use only under the direction of a licensed veterinarian. This information is not a substitute for veterinary diagnosis, prescribing or monitoring.
Commonly observed effects following the administration of Bexacat™ include an increase in urine volume (polyuria), increased thirst (polydipsia) and localized digestive changes such as a decrease in appetite or loose stools. A significant and high-priority clinical consideration for SGLT2 inhibitors is the risk of euglycemic diabetic ketoacidosis (DKA), a serious condition where the cat develops metabolic acidosis while maintaining relatively normal blood sugar levels. Your veterinarian will monitor your cat closely for any signs of lethargy, dehydration or vomiting, which warrant immediate professional attention. Owners should watch for behavioral shifts and ensure their pet remains hydrated and continues to eat consistently.
This medication is typically used with extra caution or avoided in patients with known severe renal or hepatic impairment or those presented with pre-existing ketoacidosis. It is specifically intended for cats that have not previously been addressed with insulin; veterinarians typically avoid transitioning insulin-addressed cats to bexagliflozin due to a heightened risk of metabolic complications. Before starting a protocol, ensure your veterinarian has a complete history of all other prescriptions your pet is receiving. Your veterinarian is the right person to provide guidance on the necessary monitoring frequency and the signs of metabolic distress that require prompt intervention to ensure the management approach remains suitable for your cat’s health status.
Yes. Bexacat™ is a prescription medication and can only be dispensed by a licensed pharmacy upon receipt of a valid authorization from a licensed veterinarian. Mixlab verifies all authorizations before any medication is prepared or shipped to your home.
Bexacat™ is available as a specific commercial flavored tablet designed for easy administration in cats. While Mixlab specializes in compounding many medications, this proprietary SGLT2 inhibitor is typically dispensed in its original commercial packaging to ensure the stability and precise delivery of the active ingredient as intended by the manufacturer.
Veterinarians often discuss Bexacat™ as an oral alternative to injectable insulin for specific diabetic feline patients. While insulin replaces a hormone the body is missing, Bexacat™ manages blood sugar by causing the kidneys to remove excess glucose through the urine, allowing for once-daily oral administration rather than twice-daily injections.
Euglycemic diabetic ketoacidosis is a serious metabolic condition where a cat’s body produces ketones while blood sugar levels appear normal. Because the sugar levels do not look "high," this condition can be difficult to detect without veterinary blood work, which is why monitoring for signs like vomiting or a sudden loss of appetite is essential for safety.
